Amgen Inc. (NASDAQ:AMGN) is among the 15 Blue Chip Dividend Stocks to Build a Passive Income Portfolio. BMO Capital raised Amgen’s price target to $372 from $335, citing potential gains from the Maritide Phase 2 Part 2 study. Amgen reported a 12% YoY revenue increase to $9.6 billion, driven by strong performance of key medicines like Repatha and Tezspire. The company also generated $4.2 billion in free cash flow in the third quarter of 2025. Amgen has raised dividends for 14 consecutive years and remains focused on advancing its pipeline.

Read more at Yahoo Finance: BMO Capital Lifts Amgen (AMGN) Price Target as MariTide Outlook Strengthens